Direct agonist/antagonist functions of dehydroepiandrosterone

Area of Science:

• Endocrinology
• Molecular Biology
• Hormone Receptor Signaling

Background:

• Dehydroepiandrosterone (DHEA) levels peak in fetuses and adults around age 30, declining thereafter.
• Declining DHEA is linked to reduced sex hormone levels and bone density in postmenopausal women.
• Previous understanding attributed DHEA's effects primarily to peripheral conversion into sex hormones.

Purpose of the Study:

• To investigate the direct effects of Dehydroepiandrosterone (DHEA) on androgen receptor (AR) and estrogen receptors (ER).
• To determine the binding affinities and transcriptional activities of DHEA on AR, ERalpha, and ERbeta.

Main Methods:

• In vitro binding assays to determine dissociation constants (Ki) for DHEA with AR, ERalpha, and ERbeta.
• Reporter gene assays to assess transcriptional activity (antagonism/agonism) on specific promoter elements.
• Cell proliferation assays (LNCaP cells) to evaluate functional responses to DHEA.

Main Results:

• DHEA bound to AR with a Ki of 1 microM, exhibiting transcriptional antagonism similar to bicalutamide.
• DHEA bound to ERalpha and ERbeta with Ki values of 1.1 and 0.5 microM, respectively.
• DHEA demonstrated preferential agonism for ERbeta (EC50 ~200 nM), with significant ERalpha agonism at higher concentrations.

Conclusions:

• DHEA exhibits direct, physiologically relevant activation of estrogen receptor beta (ERbeta) at nanomolar concentrations.
• DHEA acts as an antagonist for the androgen receptor (AR) and a partial agonist for ERalpha.
• These direct receptor interactions suggest novel mechanisms for DHEA's physiological and pharmacological effects.